BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 1740685)

  • 1. Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: a novel and effective method for delivering multiple courses of dose-intensive therapy.
    Shea TC; Mason JR; Storniolo AM; Newton B; Breslin M; Mullen M; Ward DM; Miller L; Christian M; Taetle R
    J Clin Oncol; 1992 Mar; 10(3):464-73. PubMed ID: 1740685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reinfusion and serial measurements of carboplatin-mobilized peripheral-blood progenitor cells in patients receiving multiple cycles of high-dose chemotherapy.
    Shea TC; Mason JR; Breslin M; Bissent E; Mullen M; Taetle R
    J Clin Oncol; 1994 May; 12(5):1012-20. PubMed ID: 7513018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy.
    Tepler I; Cannistra SA; Frei E; Gonin R; Anderson KC; Demetri G; Niloff J; Goodman H; Muntz H; Muto M
    J Clin Oncol; 1993 Aug; 11(8):1583-91. PubMed ID: 8101563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
    Shapiro CL; Ayash L; Webb IJ; Gelman R; Keating J; Williams L; Demetri G; Clark P; Elias A; Duggan D; Hayes D; Hurd D; Henderson IC
    J Clin Oncol; 1997 Feb; 15(2):674-83. PubMed ID: 9053493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy.
    Elias AD; Ayash L; Tepler I; Wheeler C; Schwartz G; Mazanet R; Schnipper L; Frei E; Antman K
    J Hematother; 1993; 2(3):377-82. PubMed ID: 7522891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer.
    Patrone F; Ballestrero A; Ferrando F; Brema F; Moraglio L; Valbonesi M; Basta P; Ghio R; Gobbi M; Sessarego M
    J Clin Oncol; 1995 Apr; 13(4):840-6. PubMed ID: 7707109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
    Krigel RL; Palackdharry CS; Padavic K; Haas N; Kilpatrick D; Langer C; Comis R
    J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose carboplatin chemotherapy with GM-CSF and peripheral blood progenitor cell support: a model for delivering repeated cycles of dose-intensive therapy.
    Shea TC; Mason JR; Storniolo AM; Bissent E; Breslin M; Mullen M; Taetle R
    Cancer Treat Rev; 1993; 19 Suppl C():11-20. PubMed ID: 8106154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
    Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Johnson S; Ozols RF
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):18-29. PubMed ID: 7544025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.
    Bunn PA; Crowley J; Kelly K; Hazuka MB; Beasley K; Upchurch C; Livingston R; Weiss GR; Hicks WJ; Gandara DR
    J Clin Oncol; 1995 Jul; 13(7):1632-41. PubMed ID: 7602352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients.
    O'Shaughnessy JA; Denicoff AM; Venzon DJ; Danforth D; Pierce LJ; Frame JN; Bastian A; Ghosh B; Goldspiel B; Miller L
    Ann Oncol; 1994 Oct; 5(8):709-16. PubMed ID: 7826903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor.
    O'Dwyer PJ; LaCreta FP; Schilder R; Nash S; McAleer C; Miller LL; Hudes GR; Ozols RF
    J Clin Oncol; 1992 Aug; 10(8):1352-8. PubMed ID: 1634926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of sequential administration of G-CSF and GM-CSF vs. G-CSF alone following peripheral blood progenitor cell autograft in solid tumors.
    Recchia F; Accorsi P; Bonfini T; De Filippis S; Grimaldi M; Corrao G; Rosselli M; Amiconi G; Iacone A; Rea S
    J Interferon Cytokine Res; 2000 Feb; 20(2):171-7. PubMed ID: 10714552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human granulocyte colony-stimulating factor infusion and/or autologous peripheral blood stem cell transplantation as a rescue for sequential high-dose combination chemotherapy: a preliminary report.
    Chau WK; Lin CK; Chow MP; Wang SY; Liu JM; Ho CH; Chiu CF; Hsu HC; Tan TD; Chan WK
    Zhonghua Yi Xue Za Zhi (Taipei); 1994 Nov; 54(5):312-20. PubMed ID: 7530591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer.
    Reed E; Janik J; Bookman MA; Rothenberg M; Smith J; Young RC; Ozols RF; VanderMolen L; Kohn E; Jacob JL
    J Clin Oncol; 1993 Nov; 11(11):2118-26. PubMed ID: 8229126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma.
    de Vries EG; Biesma B; Willemse PH; Mulder NH; Stern AC; Aalders JG; Vellenga E
    Cancer Res; 1991 Jan; 51(1):116-22. PubMed ID: 1988077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor. A randomized trial.
    Kritz A; Crown JP; Motzer RJ; Reich LM; Heller G; Moore MP; Hamilton N; Yao TJ; Heelan RT; Schneider JG
    Cancer; 1993 Apr; 71(8):2515-21. PubMed ID: 8095854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma.
    Gianni AM; Bregni M; Siena S; Orazi A; Stern AC; Gandola L; Bonadonna G
    J Clin Oncol; 1990 May; 8(5):768-78. PubMed ID: 2185337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosing regimen of granulocyte-macrophage colony-stimulating factor to support dose-intensive chemotherapy.
    Neidhart JA; Mangalik A; Stidley CA; Tebich SL; Sarmiento LE; Pfile JE; Oette DH; Oldham FB
    J Clin Oncol; 1992 Sep; 10(9):1460-9. PubMed ID: 1517789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
    Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
    Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.